FDA Approves B-VEC Topical Gene Therapy for Dystrophic Epidermolysis Bullosa
The long-awaited FDA approval follows data that demonstrated about 70% wound closure by 6 months in dystrophic epidermolysis bullosa patients treated with B-VEC.
Source: hcplive.com